NeuroLife / ActivateNeuro

NeuroLife operates at the intersection of neurotechnology, wearable medical devices, and rehabilitation. Its stated product direction is a non-invasive wearable system for hand and arm rehabilitation, aimed at people affected by stroke and spinal cord injury. The company describes an integrated approach combining high-density neuromuscular sensing, real-time interpretation of muscle activity, and adaptive stimulation. A sleeve form factor and rapid calibration are intended to fit existing therapy workflows, differentiating the offering at the product-design level from approaches centered only on monitoring or standalone stimulation. NeuroLife says its technology draws on more than a decade of research and development by Battelle’s Neurotechnology R&D team. It is a young, development-stage company founded in 2024, with one $2.9 million Seed round announced in June 2026 and a team size in the 1–10 range. Its competitive position will depend on clinical validation, usability in care settings, regulatory progress, and evidence that the combined sensing-and-stimulation approach improves functional outcomes.

NeuroLife’s trajectory reflects a shift from a long-running research effort to an independent, funded venture. The company was founded in 2024, while its technology is described as building on more than a decade of research and development within Battelle’s Neurotechnology R&D team. The main financial inflection point so far is the $2.9 million Seed round announced on Jun 25, 2026, with Battelle and The NeuroTech Institute participating. The following day, coverage of the Battelle spinout brought attention to the company’s movement-restoration device. A further organizational milestone came on Oct 7, 2026, when Christopher Coburn and Matthew Thomas were announced as new Board members, with Coburn bringing healthcare innovation experience. These milestones point to early company formation and governance development, but the next meaningful indicators will be evidence of clinical progress, product readiness, and adoption by rehabilitation providers.